Format

Send to

Choose Destination
Hum Pathol. 2016 Nov;57:1-6. doi: 10.1016/j.humpath.2016.06.011. Epub 2016 Jun 24.

B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.

Author information

1
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030.
2
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China 210029.
3
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030.
4
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA 77030. Electronic address: yzu@HoustonMethodist.org.
5
Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China 710032. Electronic address: jzhang@fmmu.edu.cn.
6
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030. Electronic address: jliu@mdanderson.org.

Abstract

The B7 family of immune costimulatory ligands is a group of cell surface proteins that bind to the surface receptors of lymphocytes to fine-tune immune responses. The aberrant expression of these proteins plays a key role in tumor immune evasion. Immunotherapy targeting certain B7 family members, including programmed death ligand 1, has proven quite effective in suppressing tumor growth. However, why such therapy works in only a subgroup of tumors is unclear. We hypothesized that other B7 family members, either alone or in concert with programmed death ligand 1, play a crucial role in tumor pathogenesis and progression. We therefore examined the expression of a newly discovered B7 family member, B7-H4, in 306 cases of ovarian serous carcinoma by immunohistochemistry. We found that 91% (267/293) of the high-grade ovarian serous carcinomas and 69% (9/13) of the low-grade ovarian serous carcinomas expressed B7-H4. The difference between B7-H4 expression in high-grade and low-grade ovarian serous carcinoma was statistically significant (P=.002). Moreover, B7-H4 protein expression in high-grade serous carcinoma was associated with tumor stage (P<.01) but not overall survival or disease-free survival. In conclusion, B7-H4 is frequently expressed in ovarian serous carcinomas, especially high-grade serous carcinomas, and may represent a novel immunotherapeutic target in this cancer.

KEYWORDS:

B7-H4; Fallopian tube; Immunohistochemistry; Immunotherapy; Ovarian cancer

PMID:
27349304
PMCID:
PMC5077670
DOI:
10.1016/j.humpath.2016.06.011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center